Therapy Areas: Autoimmune
Abpro Finalizes Strategic Partnership with Celltrion for Worldwide Development and Commercialization of a Cancer Treatment Bispecific Antibody
22 September 2022 - - US-based biotech company Abpro has forged a strategic partnership with South Korean biopharmaceutical company Celltrion for its cancer molecule ABP 102, an antibody therapy for patients suffering from HER2+ cancer, including breast, gastric, and pancreatic cancer, the company said.

Through this global partnership, Abpro will receive payments from Celltrion of up to USD 1.75bn, including an equity investment, development and commercial milestone payments and worldwide profit sharing.

Celltrion will be in charge of the development of ABP 102 following the completion of in vitro studies by Abpro and will have world-wide commercialization rights. HER2+ type cancer is implicated in up to 30% of all cases in breast, gastric, pancreatic, and other forms of cancer.

Abpro is a clinical stage biotechnology company located in Woburn, Massachusetts. The company's mission is to improve the lives of mankind facing severe and life-threatening diseases with next-generation antibody therapies.

Abpro's DiversImmune platform has been used successfully to generate monoclonal antibody therapies against 300 traditionally difficult targets.

The Diversimmune platform combines nano-immunology, next-generation sequencing, advanced engineering and bioinformatics to create monoclonal antibody therapies against traditionally difficult targets.

Abpro's MultiMab platform uses dual-targeting antibodies, or the antibody's two "arms," to grab the tumor cell with one and a T cell in the other.

This allows antibodies to simultaneously bind to tumor-specific antigen and to cytotoxic T cells to kill the tumor cells. The T cell works to destroy the tumor cell by leveraging the body's natural immune system response that eliminates foreign cells.

By including two binding sites for the tumor antigen, these molecules are designed to form a much stronger connection to tumor cells than molecules that feature only a single binding site.
The company has a pipeline of therapies to treat cancer, eye, autoimmune, infectious diseases and other areas.

A leading force in the Korean pharmaceutical industry, Celltrion achieved what was thought impossible by launching the world's first "antibody biosimilar" from a country with a relatively underdeveloped pharmaceutical sector.

The company has pioneered numerous uncharted areas to stellar success, which it plans to follow up by continuing its growth as a global biopharmaceutical company with unique approaches to small molecule pharmaceuticals and new businesses such as the Ubiquitous-healthcare platform business.
Login
Username:

Password:


Related Headlines